Mirror Site, please visit our main site www.timtec.com
39 References in ACS Publications
LDDN1 (TimTec Natural Product Library)
ChemMine
ChemDB Supplements
Colorado State University Center for Bioinformatics
Columbia Genome Center Libraries - High Throughput Screening (HTS)
University of Georgia Striepen lab
University of Maryland in Silico Compound Databases
Harvard Medical School Anti-Viral Research
Columbia University Chemical Libraries
University of Massachusetts Medical School Compounds and Antibodies
University of California San Francisco Materials and Methods
University of Miami / Journal of Biomolecular Screening
University of Maryland Chemicals
Indiana University TimTec's Bioscreening DB
Harvard Medical School Commercial Libraries
Washington University Methods
Texas A&M University Materials and Methods
Emory University Small Molecule Enhancers of Aggresome Formation
Royal Society of Chemistry References
Download SDF Files
P: 302-292-8500F: 302-292-8520 This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
IUPAC, Smiles, ID, MW, Name, CAS, MDL
Two independent exome sequencing studies have identified new genetic subtypes of prostate cancer. Presenting its findings in Nature, a University of Michigan Medical School-led team identified CHD1 mutations in 8% of heavily pretreated lethal metastatic castration-resistant prostate cancers (CRPCs). Notably, CHD1 mutations were almost always found in tumors that didn’t display ETS gene family fusions. [...]
Scientists have identified a factor in the conditioned medium of mesenchymal stem cell (MSCs) cultures that appears to play a key role in the therapeutic effects of MSC-based therapy in multiple sclerosis (MS). Studies by Case Western Reserve University researchers in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS demonstrated that treatment using conditioned [...]
Girindus has obtained the exclusive rights to develop, supply, and commercialize certain oligonucleotide constructs using Marina Biotech’s conformationally restricted nucleotide (CRN) chemistry. In return Marina will receive royalties from the sale of CRN-based oligonucleotide reagents as well as a robust supply of cGMP material for Marina and its partners’ preclinical, clinical, and commercialization needs. CRNs [...]
Roche’s Ventana Medical Systems co-exclusively sublicensed IP from Gen-Probe granting the firm in vitro diagnostic rights relating to the immunohistochemical measurement of ERG protein expression in prostate tissue. Ventana says the licensed IP complements its existing co-exclusive sublicense to IP covering in situ hybridization measurements of ETS gene rearrangements (including ERG gene rearrangements) in tissue. [...]
BioDelivery Sciences received a $2.5 million prelaunch milestone payment from Meda, triggered by the first national regulatory clearance and pricing approval for Breakyl/Onsolis (fentanyl buccal soluble film) in the EU. Breakyl is indicated for the management of breakthrough pain in opioid-tolerant adult cancer patients. BioDelivery will receive another, final $2.5 million EU-related milestone when the [...]
Osiris Therapeutics’ adult stem cell therapy Prochymal® received approval from Health Canada for the treatment of acute graft-vs-host disease (GvHD) in children who failed to respond to steroids. The company will have to carry out certain post-launch confirmatory studies. The decision gives Osiris the distinction of being the first company to win full marketing approval [...]
Scientists have adapted the algorithm used by Google’s web search engine to develop a computational program that can identify panels of biomarkers for cancer prognosis. Google’s PageRank algorithm takes into account the network of hyperlinks between web documents as well as the search terms themselves to determine which pages are most relevant to a particular [...]
Janssen Pharmaceuticals reported Phase III results demonstrating the efficacy of Nucynta® ER (extended release tapentadol) in managing pain associated with chronic diabetic peripheral neuropathy (DPN). Janssen says the data is consistent with that of a separate study reported in 2011 in patients with DPN. Nucynta ER is a centrally acting analgesic that acts as both [...]
Targeted cancer drug developer Ruga negotiated rights to Selexagen Therapeutics’ RAF kinase program. The firm claims the acquired technology addresses the drawbacks to BRAF inhibition as an approach to cancer therapy. Data has demonstrated that BRAF inhibition can actually induce adaptation in RAS-activated cells and promote the development of secondary skin lesions and RAS-mutated tumor [...]
XenoBiotic Laboratories established a partnership with Hungary-based Solvo Biotechnology to offer in vitro transporter services in the U.S. Solvo will transfer its efflux and uptake transporter assays to XBL’s research facilities in New Jersey. The services will be made available to American customers through both Solvo and XBL sales channels. Through this collaboration Solvo will [...]
User Name
Password
Remember Me